Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122380 | 1.00 | CTSL (0.39) | CTSLCTSBCTSKDRD2DRD3 | |
| SCHEMBL17504258 | 1.00 | CTSL (0.39) | CTSLCTSBCTSKDRD2DRD3 | |
| SCHEMBL12012196 | 0.94 | CTSL (0.46) | CTSLCTSBCTSKDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3522017 | 0.92 | CTSL (0.44) | CTSLCTSBCTSKDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3522018 | 0.92 | CTSL (0.44) | CTSLCTSBCTSKDRD2DRD3 | |
| SCHEMBL4089865 | 0.91 | SLC6A4 (0.38) | CTSLCTSBCTSKDRD2DRD3 | |
| SCHEMBL16122368 | 0.91 | SLC6A4 (0.38) | CTSLCTSBCTSKDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3522545 | 0.89 | DRD2 (0.37) | CTSLCTSBCTSKDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3522546 | 0.89 | DRD2 (0.37) | CTSLCTSBCTSKDRD2DRD3 | |
| SCHEMBL24603001 | 0.71 | SLC6A4 (0.39) | DRD2DRD3SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670209-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160039819-A1 | MUSCARINIC AGONISTS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039819-A1 | MUSCARINIC AGONISTS | CHRM3, CHRM2, CHRM1 | CTSL 2756/4885CTSB 2333/4885CTSK 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.